← vista completa

Publicado el 1 de junio de 2004 | http://doi.org/10.5867/medwave.2004.05.3493

Cáncer de ovario y mutaciones de los genes BRCA1 y BRCA2

Ovarian cancer and mutations of the BRCA1 and BRCA2 genes

Claudia Osorio

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Claudia Osorio

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Osorio C. Ovarian cancer and mutations of the BRCA1 and BRCA2 genes. Medwave 2004;4(05):e3493 doi: 10.5867/medwave.2004.05.3493

Publicación 01/06/2004

Métricas del artículo

Artículo no tiene métricas.

Notas

Referencias

  1. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin. 1993 Jan-Feb;43(1):7-26. | CrossRef | PubMed
  2. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996 Jun 1;77(11):2318-24. | CrossRef | PubMed
  3. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med. 1997 May 15;336(20):1401-8. | CrossRef | PubMed
  4. Steichen-Gersdorf E, Gallion HH, Ford D, Girodet C, Easton DF, DiCioccio RA, et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet. 1994 Nov;55(5):870-5. | PubMed
  5. Lynch HT, Lemon SJ, Karr B, Franklin B, Lynch JF, Watson P, et al. Etiology, natural history, management, and molecular genetics of hereditary nonpolyposis colorectal cancer: genetics counseling implications. Cancer Epidemiol Biomarkers Prev. 1997 Dec;6(12):987-91. | PubMed
  6. Wenham RM, Lancaster JM, Berchuck A. Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):483-97. | CrossRef | PubMed
  7. Cramer DW, Hutchinson GB, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983 Oct;71(4):717-21. | PubMed
  8. Whittemore AS, Harris R, Intyre J. Characteristics relating to ovarian cancer risk . Collaborative analysis of twelve case – control studies. II. Invasive epithelial ovarian cancer in white women. Am J Epidemiol. 1992 Nov 15;136(10):1184-203. | PubMed
  9. Schildkraut JM, Bastos E, Berchuk A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst. 1997 Jul 2;89(13):932-8. | CrossRef | PubMed
  10. Scully R. Role of BRCA gene disfunction in breast and ovarian cancer predisposition. Breast Cancer Res. 2000;2(5):324-30 | CrossRef | PubMed
  11. Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res. 1998 Oct;4(10):2433-7. | PubMed
  12. Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 1995 Jul 15;55(14):2998-3002. | PubMed
  13. Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997 Apr 17;336(16):1125-30. | CrossRef | PubMed
  14. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996 Nov 7;335(19):1413-6. | CrossRef | PubMed
  15. Modan B. BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med. 1997 Apr 24;336(17):1255; author reply 1256-7. | PubMed
  16. Johannsson OT, Ranstam J Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol. 1998 Feb;16(2):397-404. | PubMed
  17. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997 Mar;60(3):496-504. | PubMed
  18. Pharoah PD, Ponder BA. The genetics of ovarian cancer. Beast Practice & Research Clinical Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):449-68. | CrossRef | PubMed
  19. Grzybowska E, Siemiñska M, Zientek H, Kalinowska E, Michalska J, Utracka-Hutka B, et al. Germinale mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Acta Biochim Pol. 2002;49(2):351-6. | PubMed
  20. Robson ME. Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. Cancer Control. 2002 Nov-Dec;9(6):457-65. | PubMed
  21. Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol. 2003 Jun;89(3):494-8. | CrossRef | PubMed
  22. Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001 Mar;80(3):341-5. | CrossRef | PubMed
  23. Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, et al. Assesment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA. 1995 Feb 15;273(7):577-85. | CrossRef | PubMed
  24. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA 1 and BRCA 2. JAMA. 1997 Mar 26;277(12):997-1003. | CrossRef | PubMed
  25. Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B. Factors associated with decisios about clinical BRCA 1 / 2 testing. Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1251-4. | PubMed
  26. Bars Culver J, Hull J, Levy-Lahad E. BRCA 1 and BRCA 2 hereditary breast / ovarian cancer. Genetest. [on line] | Link
  27. Davison C, Macintyre S, Smith GD. The potential social impact of predictive genetic testing for susceptibility to common chronic diseases: a review and proposed research agenda. Sociol Health Illn. 1994 Jun;16(3):340-71. | CrossRef | PubMed
  28. Ponder M, Green JM. BRCA1 testing: some issues in moving fron research to service. Psycho-Oncology 1996 ; 5(3):223-32. | CrossRef
  29. Balmer C. BRCA 1 and BRCA 2 genetic testing for ovarian cancer: is it all good news? Eur J Oncol Nurs. 2002 Sep;6(3):162-8. | CrossRef | PubMed
  30. Bluman LG, Rimer BK, Regan Sterba K, Lancaster J, Clark S, Borstelmann N, et al. Attitudes, knowledge, risk perceptions and decision-making among woman with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses. Psychooncology. 2003 Jul-Aug;12(5):410-27. | CrossRef | PubMed
  31. Reedy M, Gallion H, Fowler JM, Kryscio R, Smith SA. Contribution of BRCA1 and BRCA 2 to Familial Ovarian Cancer: A Gynecologic Oncology Group Study. Gynecol Oncol. 2002 May;85(2):255-9. | PubMed
  32. Pericay C, Díez O, Campos B, Balmaña J, Domènech M, Lerma E, et al. Características clinicopatológicas y evolución clínica de pacientes con cáncer de mama y mutaciones en los genes BRCA 1 o BRCA 2. Med Clin (Barc). 2001 Jul 7;117(5):161-6. | PubMed